Table 3. Safety endpoint.

	Topiroxostat (n = 70)	%	Allopurinol (n = 70)	%	P Value
Adverse events, n (%)	21	30.0	14	20.0	0.17
Serious adverse events, n (%)	6	8.6	5	7.1	0.75
Unknown adverse events, n (%)	5	7.1	4	5.7	–
Probably related adverse events, n (%)	1	1.4	0	0.0	–
Serious adverse events necessitating withdrawal from the study, n (%)	1	1.4	2	2.9	–
Serious cardiovascular adverse events, n (%)	3	4.3	3	4.3	–
Gouty arthritis, n (%)	1	1.4	0	0.0	–
Hepatic function abnormality, n (%)	1	1.4	1	1.4	–

Values are n (percentage of patients). P-values are for the between-groups difference by Wilcoxon rank-sum test.